Blueprint Medicines Corporation - BPMC STOCK NEWS

Blueprint Medicines (BPMC) presented data at the 2024 ASH Annual Meeting demonstrating long-term clinical benefits of AYVAKIT (avapritinib) in advanced systemic mastocytosis (SM). Key findings include significant survival benefits in treatment-naïve patients compared to midostaurin, sustained improvements in bone density for patients with low bone mass, and evidence of immune dysregulation in indolent SM patients.

The company also highlighted a new ultra-sensitive KIT testing method in peripheral blood that identified previously undetected KIT mutations in PIONEER trial patients, suggesting SM may be more prevalent than previously thought. Additionally, Blueprint developed a machine learning model to distinguish between advanced SM and ISM, validated by Dana-Farber Cancer Institute data.

Blueprint Medicines (BPMC) reported strong Q3 2024 financial results, achieving $128.2 million in AYVAKIT net product revenues, representing 136% growth year-over-year. The company raised its full-year 2024 AYVAKIT revenue guidance to $475-480 million, up from previous guidance of $435-450 million. Q3 net loss was $56.3 million, improved from $133.7 million in Q3 2023. Cash position strengthened to $882.4 million as of September 30, 2024. The company expects declining operating expenses and cash burn in 2024 compared to 2023, while maintaining focus on long-term growth.

Blueprint Medicines (NASDAQ: BPMC) has announced that it will host a live conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and provide a corporate update. Interested parties can access the live conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) and referring to conference ID 387547.

A webcast of the call will also be available under the 'Events and Presentations' section of the company's Investors & Media webpage. The archived webcast will be accessible on Blueprint Medicines' website approximately two hours after the conference call and will remain available for 30 days following the call.

Blueprint Medicines (NASDAQ: BPMC) has announced its participation in two upcoming virtual investor conferences. The company will present at the Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET, and at TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.

Investors and interested parties can access live webcasts of both presentations through the Investors & Media section of Blueprint Medicines' website. Replays of the webcasts will be available on the company's website for 30 days following each presentation, providing an opportunity for those unable to attend the live events to catch up on the information shared.

The Schall Law Firm is investigating potential securities law violations by Blueprint Medicines (NASDAQ: BPMC). The investigation centers on whether Blueprint issued false or misleading statements to investors. On August 17, 2022, Blueprint announced top-line results from Part 2 of its PIONEER clinical trial for AYVAKIT® (avapritinib). The company revealed that the absolute improvement in symptom score decreased from 19.7 in Part 1 to 15.6 in Part 2. This news caused Blueprint's stock to fall by 10% on the same day.

Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights. The firm specializes in securities class action lawsuits and shareholder rights litigation. It's important to note that the class in this case has not yet been certified, and affected shareholders are not currently represented by an attorney unless they take action.

Blueprint Medicines reported strong Q2 2024 results, with AYVAKIT net product revenues of $114.1 million, representing over 185% year-over-year growth. The company raised its full-year 2024 AYVAKIT revenue guidance to $435-$450 million, up from $390-$410 million. Total revenues were $138.2 million for Q2 2024.

Key highlights include:

• Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808
• Presented positive combination safety data for CDK2 inhibitor BLU-222
• Expects to initiate registration-enabling HARBOR Part 2 study of elenestinib in indolent systemic mastocytosis later this year

Blueprint Medicines reported a net loss of $50.0 million for Q2 2024, compared to $132.8 million in Q2 2023. The company's cash position as of June 30, 2024, was $868.5 million.

Blueprint Medicines (NASDAQ: BPMC) has announced its plans to report second quarter 2024 financial results on Thursday, August 1, 2024. The company will host a live conference call and webcast at 8:00 a.m. ET to present the results and provide a corporate update. Interested parties can access the call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) with the conference ID 299779. A webcast will also be available on the company's website under the Investors & Media section. The archived webcast will remain accessible for 30 days following the call.

Blueprint Medicines (NASDAQ: BPMC) announced presentations at the EAACI and EHA annual meetings showcasing the durable clinical benefits of AYVAKIT® (avapritinib) for systemic mastocytosis (SM). Seven presentations, including four oral sessions, will highlight data across different studies like PIONEER, PATHFINDER, and PRISM. Key findings include sustained efficacy and safety of AYVAKIT, improved quality of life for patients, and significant overall response rates. The PRISM survey underscores the substantial impact of SM on patients' lives, emphasizing the urgency to diagnose and treat the condition. The presentations will be available on the company’s website.

Blueprint Medicines announced updated Phase 1 data for their CDK2 inhibitor, BLU-222, in combination with ribociclib and fulvestrant, for HR+/HER2- breast cancer. The study showed BLU-222 was well-tolerated with no dose-limiting toxicities. Updated data indicate significant biomarker reductions correlated with BLU-222 exposure. Early results suggest clinical activity, including one unconfirmed partial response. Detailed findings will be presented at the 2024 ASCO Annual Meeting.